N-acetylcysteine, kidilact probiotic, and oropharyngeal microbial flora

Efficacy of 20% N-acetylcysteine, Kidilact probiotic, and routine care on oropharyngeal microflora in intubated patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170316033099N9

Enrollment

Registered

2019-10-13

Start date

2019-07-23

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oropharyngeal microflora.

Interventions

Intervention 1: Group 1 (N-acetylcysteine group): puffs of 20% N-acetylcysteine spray will be used every 24 hours in the oropharynx, 0.5 ml volume at each puff. Intervention 2: Group 2 (Kidilact probi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Intubated patients admitted to the intensive care unit Signing informed consent forms for participation

Exclusion criteria

Exclusion criteria: Tracheostomy Respiration transformed from spontaneous to mechanical or vice versa Extubation Vomiting Intravenous administration of N-acetylcysteine Malplacement In the Kidilact probiotic group only: immunodeficiency, cancer, white blood cell count less than 4000, neutrophil count less than 1000, and chemotherapy

Design outcomes

Primary

Measure	Time frame
Microbial flora diversity. Timepoint: Before intervention and 24 hours after intervention. Method of measurement: Laboratory test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlieh Behrouzifar

Islamic Azad University

abehroozifar@yahoo.com+98 56 3239 1200

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026